|Day Low/High||80.28 / 81.71|
|52 Wk Low/High||67.88 / 92.85|
BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.
Mike Pence could shore up Donald Trump's support among conservative Christians, but his record on business in Indiana is spotty at best.
TheStreet highlights 3 stocks pushing the health care sector higher today.
Unique program addresses industry's lack of underrepresented minorities
Stocks with insider trader activity include APOG, LLY and SNCR
Cramer has learned what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.
The charts look favorable for these six high-yield dividend stocks. The stocks are among Deutsche Bank's list of best long ideas.
The company's shares were up nearly 2% in after hours trading.
Singer's moving story aims to help inspire children with type 1 diabetes to pursue their dreams
Following Brexit volatility, Deutsche Bank offered investors 42 best long ideas; here's the 12 stocks from the list with the highest dividend yields.
Nike's board of directors features a who's who of Fortune 500 executives.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
If Eli Lilly can blow through the $79 area, the stock has plenty of room to run on the upside.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes
What if the only sentiment-turning catalyst left for biotech stocks this year is the outcome of Eli Lilly's Alzheimer's phase III study expected around Christmas?
Regional Community Conversations Events to Spark Creation of Preparedness Plans across the Nation
Trade-Ideas LLC identified Eli Lilly and (LLY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.
Research to focus on unmet needs in animal health, including antibiotic alternatives
Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc.
This is the group that is the most dangerous politically.
Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.
Alimta Case Returned to Court of Appeal for New Ruling
-- JARDIANCE is the only SGLT2 inhibitor to demonstrate the potential to improve kidney outcomes on top of standard of care